Replenishing copper stores through IV therapy uses a modest daily amount over several days to restore copper-dependent functions and correct deficiency symptoms. The standard approach is to give 2-4 mg of elemental copper each day for six days. This range provides enough copper to replete stores and improve blood abnormalities without markedly increasing toxicity risk, and the six-day course fits typical repletion timelines before transitioning to oral maintenance. Shorter, lower dosing may fail to restore levels, while higher daily amounts or longer courses aren’t generally necessary and can raise toxicity risk. After repletion, continue with oral copper and monitor levels as needed.

Bariatric surgery eligibility for someone with a BMI of 35 or higher is often tied to obesity-related health problems. Among the common comorbidities used to support surgery approval are type 2 diabetes, obstructive sleep apnea, and non-alcoholic fatty liver disease, because these conditions are closely linked to obesity and typically improve after weight loss. Vitamin D deficiency, while very common in obesity, is a nutritional deficiency rather than a disease state used to justify surgical qualification, so it isn’t listed as a qualifying comorbidity. That’s why this option is the one that isn’t counted toward the BMI 35 surgery criteria.

In youths 16 and older, pharmacologic options for obesity are limited and must be used alongside lifestyle changes. Among the listed choices, the medication that is appropriate for this age group is orlistat. Orlistat works by inhibiting pancreatic lipase, which reduces fat absorption from the diet. Because weight loss with this drug depends on dietary fat intake, it’s most effective when paired with a reduced-calorie diet and regular physical activity. Side effects are mainly gastrointestinal, such as oily stools or flatulence with discharge, and it can reduce absorption of fat-soluble vitamins, so a multivitamin is usually recommended at a different time than the orlistat dose. Sibutramine, historically used as an appetite suppressant, has been withdrawn from the market due to serious cardiovascular safety concerns and is not used in youths. Very low-calorie diet and regular exercise are important foundations of obesity management but are not medications.

The idea behind choosing an obesity drug is to weigh how well it helps with weight loss against how well patients tolerate it and what safety risks it carries. Lorcaserin works by selectively activating serotonin-2C receptors in the hypothalamus, which dampens appetite and leads to lower caloric intake. This tends to produce modest but meaningful long-term weight loss with a generally favorable tolerability profile, especially compared with stimulant-like drugs. Orlistat lowers weight by inhibiting fat absorption, but the downside is mainly gastrointestinal issues that can limit adherence and yield only modest weight loss. Topiramate, either alone or combined with phentermine, can produce more substantial weight loss but brings cognitive effects and other tolerability concerns, and the combination carries additional risks such as teratogenicity and cardiovascular considerations. Given these trade-offs, lorcaserin is often viewed as the better-balanced option for many patients seeking pharmacologic treatment for obesity, offering consistent appetite suppression with a tolerable safety profile.